2020
DOI: 10.17235/reed.2020.6392/2019
|View full text |Cite
|
Sign up to set email alerts
|

The efficacy of glucagon-like peptide 1 receptor agonists in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
6
0
1

Year Published

2020
2020
2023
2023

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 8 publications
(8 citation statements)
references
References 35 publications
1
6
0
1
Order By: Relevance
“…In line with our results, a previous meta‐analysis revealed that GLP‐1 RA therapy significantly increases adiponectin (WMD 0.66 μg/mL, 95% CI 0.37–0.95, P < .001) 37 . However, this finding was obtained in a subgroup analysis of secondary outcomes that only included 3 randomized controlled trials in patients with nonalcoholic fatty liver disease.…”
Section: Discussionsupporting
confidence: 91%
See 1 more Smart Citation
“…In line with our results, a previous meta‐analysis revealed that GLP‐1 RA therapy significantly increases adiponectin (WMD 0.66 μg/mL, 95% CI 0.37–0.95, P < .001) 37 . However, this finding was obtained in a subgroup analysis of secondary outcomes that only included 3 randomized controlled trials in patients with nonalcoholic fatty liver disease.…”
Section: Discussionsupporting
confidence: 91%
“…In line with our results, a previous meta-analysis revealed that GLP-1 RA therapy significantly increases adiponectin (WMD 0.66 μg/mL, 95% CI 0.37-0.95, P < .001). 37 However, this finding was obtained in a subgroup analysis of secondary outcomes that only included 3 randomized controlled trials in patients with nonalcoholic fatty liver disease. Furthermore, our meta-analysis demonstrated a greater impact of GLP-1 RA on adiponectin levels than a low-calorie diet (0.34 μg/mL, 95% CI 0.17-0.50), 38 exercise (WMD 0.44 μg/mL; 95% CI 0.13-0.75), 39 metformin treatment (WMD 0.19 μg/mL; 95% CI 0.09-0.30), 40 and sodium-glucose cotransporter 2 inhibitor treatment (WMD 0.30 μg/mL; 95% CI 0.22-0.38), 41 and a similar effect to dipeptidyl peptidase-4 inhibitors (WMD 0.74 μg/mL; 95% CI 0.45-1.03).…”
Section: F I G U R E 1 Flow Chart Of the Number Of Studies Included For Meta-analysismentioning
confidence: 99%
“…In the past decade, there have been some meta-analyses for GLP-RA treatment of MAFLD ( 33 , 34 ). Dong et al ( 33 ) evaluated three RCTs and three observational studies (a total of 329 people), among which one RCT and two observational trials used liver pathological biopsy as a diagnostic method.…”
Section: Discussionmentioning
confidence: 99%
“…They observed that pioglitazone decreases liver steatosis but that they have no effect on liver fibrosis and inflammation. It has been observed that treatment with a GLP-1 receptor antagonist improves body mass index, adiponectin, and liver fat fraction in NAFLD patients [ 74 ]. The second group of drugs targets inflammation and oxidative stress.…”
Section: Diagnosis and Management Of Nafld In Pcos And Future Investigationsmentioning
confidence: 99%